Elderberry’s Anti-viral Activity: An Update

By Maxwell Crispo, ND, and Michael Traub, ND, DHANP, FABNO

December 04, 2019

European elder (Sambucus nigra), also known as black elder and elderberry, is thought to be beneficial for the prevention and treatment of influenza and upper respiratory infections, though there is still debate as to which stage of infection it is most effective in and even what the exact mechanisms of action are that lend elderberry its anti-viral effects. American elder (Sambucus canadensis) is a fast-growing, deciduous North American shrub that can reach up to 12 feet with flowers and berries similar to S. nigra. Elder flower extracts are also used to treat the common cold and influenza. This review will confine discussion to European elder berries only.

A recent in vitro study published in the Journal of Functional Foods by Torabian et al1 investigated the mechanism of action of elderberry and its primary anthocyanin compound, cyanidin 3-glucoside, on the infectivity of the influenza virus. The study evaluated pasteurized, whole-elderberry extract at different concentrations, as well as the isolated bioactive compound cyanidin 3-glucoside at different concentrations. The primary outcome assessed was the effect of these extracts at different concentrations on influenza viral activity at different stages of infection.

While elderberry was shown to have inhibitory effect at all stages of influenza infection, it had a significantly stronger effect on the late-stage of infection than at early stage; smaller concentrations (higher dilutions) of elderberry had partial or no inhibitory effect during the early phase but those same concentrations had significant inhibitory effect during the late-phase of infection. Furthermore, the antiviral activity of elderberry on influenza was strongest when used in pre-treatment, during infection and post-infection, rather than when used solely during infection. The study confirmed that elderberry exerts its antiviral activity on influenza through a number of mechanisms of action, including suppressing the entry of the virus into cell, modulating the post-infectious phase, and preventing viral transmission to other cells. Elderberry also upregulates IL-6, IL-8 and TNF, suggesting an indirect effect on viral immune response in the body. Interestingly, elderberry was shown to have this effect but not its major bioactive compound, cyanidin 3-glucoside.

No human clinical trials have been published on the prevention of influenza with elderberry, however, black elderberry extract has previously been shown to inhibit human influenza A (H1N1) infection in vitro by binding to H1N1 virions, thereby blocking the ability of the viruses to infect host cells.2 The same study showed elderberry to be effective against 10 strains of influenza virus and compared its effectiveness favorably to the known anti-influenza activities of oseltamivir (Tamiflu) and amantadine.

The mechanistic study conducted by Torabian et al and summarized above was published nearly at the same time as the first meta-analysis of 4 randomized controlled trials on the effects of elderberry supplementation on acute upper respiratory symptoms.3 Three of the studies (Zakay-Rones 1995,4 2004;5 Tiralongo 20166) evaluated total duration of upper respiratory symptoms. Another study, Kong 2009,7 measured symptoms throughout a 48-hour intervention across 6 symptom scales. The meta-analysis included 89 participants in the elderberry group and 91 in the control group (total 180). Three of the studies evaluated the effects of elderberry treatment for either verified cases of influenza or cases with symptoms consistent with influenza infection. The other study evaluated the effects of elderberry on symptoms consistent with the common cold.

A large effect size (ES) was found, 1.717 (P<0.001), indicating elderberry substantially reduced duration of upper respiratory symptoms. Flu vaccination status was controlled for and found to not impact the overall effect of elderberry supplementation on upper respiratory symptoms. Elderberry appears to reduce symptoms caused by influenza virus (ES: 2.074) substantially more effectively than upper respiratory symptoms caused by the common cold (ES: 0.662), although the effect on cold symptoms is still within the standard for a medium effect.

The Tiralongo trial on elderberry’s effect on symptoms of the common cold in air travelers did not reach statistical significance, but the dose of 90—135 mg of anthocyanins daily was far lower than that used in the Zackay-Rones trials (1,900 mg daily).8 Kong’s trial used a 175 mg extract 4 times daily for 2 days. This reflects a wide variation in commercially available elderberry extracts.

These findings present an alternative to antibiotic misuse for upper respiratory symptoms due to viral infections, and a potentially safer alternative to prescription drugs for routine cases of the common cold and influenza. Elderberry seems to be most effective when used before and throughout infection, though a higher concentration may be required in the early infective stages to achieve significant anti-viral activity.

*A note on safety: elderberries contain cyanogenic glycosides (i.e. sambunigrin) which are hydrolyzed to hydrogen cyanide in the gastrointestinal tract.9 Ingestion of uncooked products from elderberry species in the United States have resulted in poisoning and hospitalization.10 Smaller doses of these glycosides do not typically result in hospitalization, but can produce gastric complaints, such as nausea, vomiting, and diarrhea, particularly in children.11

About the Authors

Maxwell Crispo, ND attended the Canadian College of Naturopathic Medicine and graduated as valedictorian for his class in 2018. He is the current resident naturopathic physician at Lokahi Health Center in Kailua-Kona, Hawaii; the clinical practice of Michael Traub, ND, FABNO. Crispo has been interested in research regarding natural health since his undergrad, where he conducted an addendum study to a clinical nutrition trial at the University of Guelph investigating the informed consent process in clinical nutrition research. In 2017, he was awarded the Anna MacIntosh Investigator Award for his proposed clinical trial investigating the efficacy of n-acetyl-l-carnitine on chemotherapy-induced peripheral neuropathy in cancer patients. Crispo currently serves as a research site coordinator for the Canada-United States Integrative Oncology Study (CUSIOS), a multicentre clinical research study on advanced naturopathic integrative therapies in the treatment of advanced stage solid-tumour cancers. For more information visit http://www.lokahihealth.com/maxwell-crispo/

Michael Traub, ND, DHANP, FABNO, completed pre-med studies at the University of California at Irvine. He graduated from National University of Naturopathic Medicine in 1981 and completed a residency there in Family Practice and Homeopathy. In 2006, Traub was honored with the American Association of Naturopathic Physicians (AANP) Physician of the Year Award in recognition for his many years of service, which included serving as AANP president from 2001 to 2003. His father was a dermatologist, and this inspired Traub to undertake extra study in this subject and become the leading expert in dermatology in the naturopathic profession. He has taught dermatology at 5 of the 7 accredited naturopathic medical schools in North America and is the author of Essentials of Dermatologic Diagnosis and Integrative Therapeutics. A fellow of the American Board of Naturopathic Oncology, Traub has been actively engaged in clinical research throughout most of his career and is currently a co-investigator in the Canadian/US Integrative Oncology Study. His most recent major publication, “Impact of Vitamin D3 Dietary Supplement Matrix on Clinical Response,” appears in a 2014 issue of the Journal of Clinical Endocrinology and Metabolism. Traub has served as medical director of Lokahi Health Center in Kailua Kona, Hawaii for the past 34 years.

References

  1. Torabian G, Valtchev P, Adil Q, Dehghani F. Anti-influenza activity of elderberry (Sambucus nigra). Journal of Functional Foods. 2019;54:353-360. doi:10.1016/j.jff.2019.01.031
  2. Roschek B, Fink RC, McMichael MD, Li D, Alberte RS. Elderberry flavonoids bind to and prevent H1N1 infection in vitro. Phytochemistry. 2009;70:1255-1261.
  3. Hawkins, J., Baker, C., Cherry, L., &amp; Dunne, E. Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials. Complementary Therapies in Medicine. 2019; 42:361–365.
  4. Zakay-Rones, Z., Varsano, N., Zlotnik, M., et al. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. The Journal of Alternative and Complementary Medicine. 1995;1(4):361-369.
  5. Zakay-Rones, Z., Thom, E., Wollan, T., Wadstein, J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. Journal of International Medical Research. 2004;32(2): 132-140.
  6. Tiralongo, E., Wee, S. S., &amp; Lea, R. A. Elderberry supplementation reduces cold duration and symptoms in air-travelers: A randomized, double-blind placebo-controlled clinical trial. Nutrients. 2016; 8(4):182.
  7. Kong, F. K. Pilot clinical study on a proprietary elderberry extract: efficacy in addressing influenza symptoms. Online Journal of Pharmacology and Pharmacokinetics. 2009;5: 32-43.
  8. Traub, M. Benefits of Elderberry for Symptoms of Common Cold in Air Travelers. Natural Medicine Review. 2016; 8:101;18-20
  9. Vlachojannis, J. E., Cameron, M., Chrubasik, S. A systematic review on the sambuci fructus effect and efficacy profiles. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2010; 24(1): 1-8.
  10. Centers for Disease Control (CDC). Poisoning from elderberry juice-- California. MMWR. Morbidity and mortality weekly report. 1984; 33(13): 173.
  11. Knudsen, B. F., Kaack, K. V. A review of human health and disease claims for elderberry (sambucus nigra) fruit. International Symposium on Elderberry. 2013; 1061:121-131.